The reason was that we had what we needed. You're right—there was mRNA hesitancy, but we had non-mRNA options that were already on the table. Actually, that's a success of the advance purchase agreement we did, because that way we not only had mRNA, but we had non-mRNA options. At that point in time, Canada had the vaccines it needed, and it meant that we didn't need to proceed with Medicago. Therefore, that was the right decision.
